Nextcure presented nc410 data at the extracellular matrix (ecm) pharmacology congress in europe on overcoming clinical limitations to immunotherapy through remodeling tumor ecm

Beltsville, md., june 27, 2022 (globe newswire) -- nextcure, inc.  (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, presented in vivo data at the 2022 ecm pharmacology congress in copenhagen that demonstrated nc410 remodels tumor ecm, enhances immune cell infiltration, alleviates immunosuppression, and reduces tumor growth in a humanized mouse tumor model.
NXTC Ratings Summary
NXTC Quant Ranking